全球瞩目的2025年欧洲肿瘤内科学会年会（ESMO Congress 2025）将于10月17日至21日在德国柏林盛大召开。
7月25日，ESMO官网已公布了除LBA之外的常规摘要题目及讲者信息。【肿瘤资讯】特此整理了泌尿肿瘤领域入选Proffered Paper Session与Mini Oral Session的重磅临床研究，带您一睹前沿风采。
优选口头报告:
泌尿肿瘤, 前列腺癌 ，阴茎癌和睾丸癌
2383O
Title：A Phase 3 study of capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281
标题：Capivasertib (capi)+阿比特龙（abi）对比安慰剂（pbo）+阿比特龙用于PTEN缺失的初治转移性激素敏感性前列腺癌（mHSPC）患者的3期研究：CAPItello-281
讲者：Karim Fizazi (Villejuif, France)
优选口头报告1:
泌尿肿瘤, 肾癌 & 尿路上皮癌
尚未公布
优选口头报告2:
泌尿肿瘤, 肾癌 & 尿路上皮癌
3068O
Title：Adjuvant nivolumab vs placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274
标题：纳武利尤单抗辅助治疗对比安慰剂用于高风险肌层浸润性尿路上皮癌的5年疗效及ctDNA结果：CheckMate 274研究
讲者：Matthew D. Galsky (New York, United States of America)
迷你口头报告:
泌尿肿瘤, 前列腺癌 ，阴茎癌和睾丸癌
2384MO
Title：First interim efficacy analysis of the Phase 1/2 PETRANHA trial of saruparib + androgen receptor pathway inhibitors (ARPI) in patients (pts) with metastatic prostate cancer (mPC)
标题：PETRANHA 1/2期研究首次中期疗效分析：saruparib联合雄激素受体通路抑制剂（ARPI）治疗转移性前列腺癌（mPC）患者
讲者：Arun A. Azad (Melbourne, Australia)
2385MO
Title：Translational analyses of T-cell phenotypes and their association with clinical efficacy in the first-in-human (FIH) trial of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC)
标题：JNJ-78278343（pasritamig）在转移性去势抵抗性前列腺癌（mCRPC）中的首次人体（FIH）试验：T细胞表型转化分析及其与临床疗效的关联
讲者：Karen Autio (New York, United States of America)
迷你口头报告1:
泌尿肿瘤, 肾癌 & 尿路上皮癌
2591MO
Title：Efficacy of Cabozantinib and Nivolumab in Cluster 1/2 Metastatic Clear Cell Renal Cell Carcinoma: Results from OPTIC RCC, a phase II trial of a novel RNAseq-based biomarker
标题：卡博替尼与纳武利尤单抗在Cluster 1/2转移性透明细胞肾细胞癌中的疗效：基于RNA测序新型生物标志物的II期OPTIC RCC研究结果
讲者：Scott M. Haake (Nashville, United States of America)
2592MO
Title：Fruquintinib (FRUQ) plus sintilimab (SIN) versus axitinib (AXI) or everolimus (EVE) monotherapy as 2L treatment in pts with locally advanced or metastatic renal cell carcinoma (RCC): results from phase 3 part of a randomized, open-label, active-controlled phase 2/3 study (FRUSICA-2)
标题：呋喹替尼（FRUQ）联合信迪利单抗（SIN）对比阿昔替尼（AXI）或依维莫司（EVE）单药治疗局部晚期或转移性肾细胞癌（RCC）的疗效：随机、开放标签、阳性对照2/3期研究（FRUSICA-2）的3期结果
讲者：叶定伟 (上海, 中国)
3069MO
Title：Health-related quality of life (HRQoL) outcomes from the NIAGARA trial of perioperative durvalumab (D) plus neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC)
标题：NIAGARA试验中围手术期度伐利尤单抗（D）联合新辅助化疗（NAC）治疗肌层浸润性膀胱癌（MIBC）的健康相关生活质量（HRQoL）结果
讲者：Michiel S. Van der Heijden (Amsterdam, Netherlands)
3070MO
Title：Phase 1 study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solid tumors (FORAGER-1): Dose optimization
标题：LY3866288（一种强效、高亚型选择性的FGFR3抑制剂）在FGFR3基因改变晚期实体瘤中的1期研究（FORAGER-1）：剂量优化
讲者：Alexandra Drakaki (Los Angeles, United States of America)
2593MO
Title：Lymphocyte activation gene-3 (LAG3) expression patterns and immunotherapy (IO) response in metastatic renal cell carcinoma (mRCC)
标题：转移性肾细胞癌（mRCC）中淋巴细胞激活基因-3（LAG3）的表达模式与免疫治疗（IO）反应
讲者：Rana R. McKay (La Jolla, United States of America)
迷你口头报告2:
泌尿肿瘤, 肾癌 & 尿路上皮癌
2594MO
Title：Association of circulating kidney injury molecule-1 (KIM-1) levels with clinical outcomes in advanced renal cell carcinoma (aRCC): Retrospective analysis of COSMIC-313
标题：循环肾损伤分子-1（KIM-1）水平与晚期肾细胞癌（aRCC）临床结局的关联：COSMIC-313研究的回顾性分析
讲者：Wenxin Xu (Boston, United States of America)
3071MO
Title：Disitamab Vedotin plus Tislelizumab as Nephron-Sparing Therapy for High-Risk Upper Tract Urothelial Carcinoma: The Phase II DISTINCT-I Trial
标题：维迪西妥单抗联合替雷利珠单抗（Tislelizumab）作为保肾疗法治疗高风险上尿路尿路上皮癌：II期DISTINCT-I试验
讲者：黄吉炜 (上海, 中国)
2595MO
Title： Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment
标题：SUNNIFORECAST试验中嫌色细胞肾细胞癌的探索性分析：比较伊匹木单抗联合纳武利尤单抗对比标准治疗作为一线方案
讲者：Marit Ahrens (Frankfurt am Main, Germany)
2596MO
Title：Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma (RCC), a Kidney Cancer Research Consortium Study.
标题：Ib/II期临床试验：伊匹木单抗、纳武利尤单抗联合 Ciforadenant（腺苷A2a受体拮抗剂）一线治疗晚期肾细胞癌（RCC）——肾癌研究联盟研究
讲者：Kathryn Beckermann (Chattanooga, United States of America)
3072MO
Title：Datopotamab deruxtecan (Dato-DXd) + rilvegostomig (rilve) in patients (pts) with locally advanced or metastatic urothelial cancer (a/mUC): Results from the phase 2 TROPION-PanTumor03 study
标题：Datopotamab deruxtecan（Dato-DXd）（Dato-DXd）联合rilvegostomig（rilve）治疗局部晚期或转移性尿路上皮癌（a/mUC）患者的疗效：2期TROPION-PanTumor03研究结果
讲者：Sun Young Rha (Seoul, United States of America)
2597MO
Title： [68Ga]Ga-DPI-4452 PET/CT for Staging of Patients with Clear Cell Renal Cell Carcinoma
标题：[68Ga]Ga-DPI-4452 PET/CT在肾透明细胞癌患者分期中的应用
讲者：Alina T. Küper (Essen, Germany)
2598MO
Title：The Intratumor Mycobiome Promotes Clear Cell Renal Cell Carcinoma Progression via Neutrophil-Mediated Immune Suppression
标题：肿瘤内真菌组通过中性粒细胞介导的免疫抑制促进肾透明细胞癌进展
讲者：Kangli Ma (上海，中国)
ESMO官网
排版编辑：肿瘤资讯-CY
苏公网安备32059002004080号
